We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,161

Digital health law update Vol. 1 Issue 4
  • Jones Day
  • USA
  • August 7 2015

With exponential growth occurring in the availability of telemedicine and other digital health products and services, patent disputes are sure to


Rights to your genomic information
  • Fish & Richardson PC
  • USA
  • November 11 2014

What rights do you have to your genomic information? In a recent panel discussion of this topic, and perhaps not surprisingly, the answer of the


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry titled "Circumstances that Constitute Delaying, Denying, Limiting


Precision Medicine Initiative moves forward with new guidelines and funding opportunities
  • Hogan Lovells
  • USA
  • December 2 2015

The White House released the Precision Medicine Initiative (PMI) Privacy and Trust Principles, aimed at building patient trust and protecting patient


Federal Circuit Limits the Safe Harbor Provision and the Scope of 271(g)
  • McDermott Will & Emery
  • USA
  • December 23 2015

Addressing issues of infringement under 35 U.S.C. 271(g) and the safe harbor provision of 271(e), the U.S. Court of Appeals for the Federal


Copyright for Engineered DNA (Part 2)
  • GQ Life Sciences
  • USA
  • March 1 2016

With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of


Claims in salbutamol complaint are adequately pled
  • Morris James LLP
  • USA
  • March 30 2016

The disputed technology relates to processes for making optically pure (R) and (S) salbutamol. Defendant moves to dismiss claims of induced


Copyright for Engineered DNA
  • GQ Life Sciences
  • USA
  • February 23 2016

With the United States Supreme Court ruling in Myriad,the enforceability of certain claims in existing gene patents and the broader patentability of


ClearCorrect: ITC and Patentee Align Submit Petitions for Rehearing En Banc, Asking Federal Circuit to Reconsider Whether the ITC Has Jurisdiction Over Digital Imports
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 29 2016

On January 27, 2016, the International Trade Commission (ITC) formally requested a rehearing en banc of a November 10, 2015, Federal Circuit panel


USPTO's Patent Subject Matter Eligibility Roundtable on Dec. 5, 2015
  • Fenwick & West LLP
  • USA
  • December 1 2016

On December 5, 2016 the USPTO will hold its second Patent Subject Matter Eligibility Roundtable to discuss issues in patent eligibility. The USPTO